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Abstract
Background: Although a number of studies have assessed the management of mania in routine clinical practice,
no studies have so far evaluated the short- and long-term management and outcome of patients affected by bipolar
mania in different European countries.
The objective of the study is to present, in the context of a large multicenter survey (EMBLEM study), an overview
of the baseline data on the acute management of a representative sample of manic bipolar patients treated in the
Italian psychiatric hospital and community settings. EMBLEM is a 2-year observational longitudinal study that
evaluates across 14 European countries the patterns of the drug prescribed in patients with bipolar mania, their
socio-demographic and clinical features and the outcomes of the treatment.
Methods: The study consists of a 12-week acute phase and a ≤ 24-month maintenance phase. Bipolar patients
were included into the study as in- or out-patients, if they initiated or changed, according to the decision of their
psychiatrist, oral antipsychotics, anticonvulsants and/or lithium for the treatment of an episode of mania.
Data concerning socio-demographic characteristics, psychiatric and medical history, severity of mania, prescribed
medications, functional status and quality of life were collected at baseline and during the follow-up period.
Results: In Italy, 563 patients were recruited in 56 sites: 376 were outpatients and 187 inpatients. The mean age
was 45.8 years. The mean CGI-BP was 4.4 (± 0.9) for overall score and mania, 1.9 (± 1.2) for depression and 2.6
(± 1.6) for hallucinations/delusions. The YMRS showed that 14.4% had a total score < 12, 25.1% ≥ 12 and < 20,
and 60.5% ≥ 20. At entry, 75 patients (13.7%) were treatment-naïve, 186 (34.1%) were receiving a monotherapy
(of which haloperidol [24.2%], valproate [16.7%] and lithium [14.5%] were the most frequently prescribed) while
285 (52.2%) a combined therapy (of which 8.0% were represented by haloperidol/lithium combinations). After a
switch to an oral medication, 137 patients (24.8%) were prescribed a monotherapy while the rest (415, 75.2%)
received a combination of drugs.
Conclusion: Data collected at baseline in the Italian cohort of the EMBLEM study represent a relevant source
of information to start addressing the short and long-term therapeutic strategies for improving the clinical as well
as the socio-economic outcomes of patients affected by bipolar mania. Although it's not an epidemiological
investigation and has some limitations, the results show several interesting findings as a relatively late age of onset
of bipolar disorder, a low rate of past suicide attempts, a low lifetime rate of alcohol abuse and drug addiction.
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Background
Although recent surveys have assessed the management of
mania in routine clinical practice [1-3], no studies with a
large sample of patients, have been conducted to evaluate
the management of manic patients in terms of clinical
(e.g., symptom profile and severity), functional (e.g.,
work, social relations, health-related quality of life) and
economic (e.g., direct and indirect medical costs) out-
comes, throughout different countries. Therefore, there is
still an opportunity to learn more about how patients
with mania are treated in different clinical practice and the
extent to which the outcomes obtained in a naturalistic
setting compare with those coming from the "efficacy tri-
als".
Moreover, the availability of new drugs for the manage-
ment of bipolar disorders has widened the therapeutic
options for the clinicians, especially in the use of com-
bined therapies and concomitant medications, which
may vary across different countries and across different
geographical areas within the same country.
The European Mania in Bipolar Longitudinal Evaluation of
Medication (EMBLEM) study is a study sponsored by Eli
Lilly and company that is being conducted to address the
need for further information from different practice, con-
cerning the drug treatment of patients with bipolar mania
(euphoric and mixed) and their clinical, functional and
economic outcomes in the short and long-term. The main
focus of EMBLEM is to describe and assess outcomes
among patients treated with antipsychotics, mood stabi-
lizers and drug combinations.
The EMBLEM study offers for the first time the opportu-
nity of collecting and analysing in the Italian psychiatric
context, clinical and psychosocial data of a large sample of
manic bipolar patients and the drug treatment they
received in a naturalistic setting.
This study will evaluate long-term effects, such as compli-
ance, length of therapy, tolerability and quality of life,
which will be measured in the 24-month maintenance
phase of the study. In addition, it will elucidate the atti-
tude of Italian specialists towards maintenance treatment.
Methods
EMBLEM is a prospective, observational (non-interven-
tional) study, aimed at evaluating approximately 4000
patients across 500 psychiatric sites in 14 European coun-
tries (Belgium, Denmark, Finland, France, Germany,
Greece, Ireland, Italy, the Netherlands, Norway, Portugal,
Spain, Switzerland and UK).
The primary aim of this study was to assess, from the start
of a new episode of acute mania and during a follow-up
period of 12 months, the pattern of "antimanic" drugs
prescribed in a routine clinical practice and the outcomes
of patients who received such prescriptions.
The study included the assessment of clinical, functional
and socio-economic outcomes of the treatment during the
acute episode and in the maintenance phase. Observa-
tions took place within the normal pattern of care on six
occasions within the Acute Phase (baseline to 12 weeks)
and four further occasions in the Maintenance Phase (up
to 24 months). The present article is only focused on base-
line data collected in bipolar manic patients in 56 Italian
sites.
The participating psychiatrists enrolled patients aged ≥ 18
years, who presented within the standard course of care as
in-or out-patients for the treatment of acute mania in the
context of bipolar disorder, if they initiated or changed
oral medication (antipsychotics, anticonvulsants and/or
lithium) for the treatment of mania. Patient consent was
obtained according to local regulation. Consent of an
appropriate legal authority was collected in the case that a
patient was not able to provide the informed consent at
the time of the baseline data collection.
Patients with a first episode of mania were eligible for
inclusion in the study if, in the opinion of the investiga-
tor, the patient had a probable diagnosis of bipolar disor-
der at the time of the start or change with an oral
medication.
As regulatory guidelines are different through European
countries participating in the EMBLEM study, where
investigators were asked to include in the study half of
patients initiated or changed to olanzapine [4], the Italian
(and Danish) patients were selected by investigators with
no restrictions regarding treatment. Participating investi-
gators were asked to take treatment decisions, including
the initial oral treatment change, independently from par-
ticipation in the EMBLEM study.
Participating patients could receive an add-on therapy,
according to standard care of acute mania. Patients who
had medications changed or stopped at any time after the
baseline observation were kept in the study, as drug dis-
continuation was not a criterion for study withdrawal.
Baseline data collection was performed within 24 hours
from the first change or start with an oral medication dur-
ing the patient admission or in the outpatient setting. The
acute phase of the study included data collection after 1,
2, 3, 6 and 12 weeks after baseline, whereas observations
during the follow-up took place at 6, 12, 18 and 24
months.BMC Psychiatry 2007, 7:33 http://www.biomedcentral.com/1471-244X/7/33
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If an inpatient was discharged before or at 12 weeks, then
a discharge observation and data collection was com-
pleted within 24 hours. Observations for patients who
had been discharged prior to 12 weeks, but who were then
readmitted before completion of the 12-week acute phase,
continued according to the normal schedule, whenever
possible.
The acute phase included the following measures: demo-
graphic data, psychiatric history, functional health status,
clinical condition, drug already received and prescribed at
baseline, concomitant medications, and quality of life.
Other outcome measures at baseline included adverse
reactions caused by therapies taken prior to enter the
EMBLEM study, medical resource use and healthcare costs
of the prescribed drugs.
Baseline socio-demographic, psychiatric history and clin-
ical data were collected to characterize the patient sample
and detect initial differences between the prescribed ther-
apies. The main outcome variable of the study is the Clin-
ical Global Impression – Bipolar Disorder (CGI-BP),
which is a CGI scale modified specifically for use in assess-
ing global illness severity and change in patients with
bipolar disorder [5]. The CGI-BP overall, mania, depres-
sion and hallucinations/delusions were assessed using a
1–7 scoring rate for severity. Symptoms of mania and
depression in the acute phase were measured using the
Young Mania Rating Scale (YMRS) [6] and 5-item (i.e.
depression, dysphoria, hedonism, psychosis and activa-
tion) Hamilton Depression Rating Scale (HAM-D) [7].
The Life Chart Methodology [8] was used in the 4 weeks
preceding study entry and throughout the study. Two
individual items from the Slice of Life [9] measured the
patient outcomes in terms of work functioning and life
satisfaction.
Investigators and sites were selected on the basis of their
willingness to take part in the study, among those operat-
ing in a wide range of treatment services, facilities and
locations (e.g. urban and rural, or Northern, Central and
Southern Italy). The case record forms permitted a simple
and easy data collection in order that observations could
be easily integrated into the daily practice of the partici-
pating physicians. The collected data were sent by each
local investigator to the country coordinator, prior to be
forwarded to the Data Entry and Management Centre in
Madrid, Spain.
In addition to the recruitment of investigators, additional
clinical, research and policy experts took part in the study
via a European Advisory Board, which included at least
one non-sponsor representative of each participating
country.
Results
Demographics
Five hundred and sixty-three patients (305 females, 254
males and 4 with missing data) were recruited in a total of
56 Italian sites. Of these, 376 (66.8%) were outpatients
and 187 (33.2%) were inpatient. The mean age was 45.8
(± 13.5) years in the total population (range 18–79), 46.9
(± 13.5) years in females and 44.5 (± 13.4) years in males;
the corresponding values of BMI were 26.7 (± 5.4), 26.5
(± 5.5) and 27.0 (± 5.2 kg/m2), respectively. Five patients
did not have any education, 119 (21.3%) completed the
primary school, 246 (44.1%) the lower/upper secondary
school, and the remaining had a post-secondary voca-
tional training or a University degree (information is
missing in 5 patients). The vast majority of patients were
outpatients (67%); no formal comparisons between hos-
pitalized and outpatients were performed.
Psychiatric history
Psychiatric history and admission details of the sample
are briefly summarised in Table 1. The mean age of onset
of symptoms was 29.7 (± 11.1) years and the mean age at
first treatment was 31.3 (± 10.9) years.
The present was the first episode in 32 patients (6.6%).
The number of patients that exhibited 1, 2, 3 and > 4
manic or mixed episodes in the past 12 months was 255
(45.6%), 175 (31.3%), 59 (10.6%) and 42 (7.5%),
respectively; the information was unknown in 32
patients. A total amount of 254 patients (45.4%) did not
have depressive episodes in the past 12 months, while 173
(30.9%) had one episode and 85 (15.2%) more than one.
One manic-mixed depressive episode was experienced by
138 (27.6%) patients, while 362 (72.4%) had more than
one episode in the past 12 months (104 had > 4 epi-
sodes). The number of patients with rapid cycles in the
previous 12 months was 104 (20.8%).
A total of 117 patients (21.1%) attempted suicide in the
past, 26 (4.7%) of them in the previous 12 months (9
more than once). Details on alcohol/cannabis/drug abuse
are shown in Table 1. In the past, 105 (19.0%) patients
had alcohol problems, 57 (10.2%) had problems with
cannabis and 27 (4.8%) with other substances.
Social status
A number of 231 patients (41.1%) were single, while 260
(46.3%) were married (whereby 5.7% were not living
together) and 71 (12.6%) had a partner. Most of patients
lived in independent residence (n = 245, 43.6%) or in a
residence as dependent family member (n = 279, 49.6%).
A total of 121 patients (21.5%) never took part in social
activities in the previous 4 weeks, 58 (10.3%) took part
once and the rest (68.1%) more than once. Eighty-seven
patients (15.5%) had no impairment in work activities,BMC Psychiatry 2007, 7:33 http://www.biomedcentral.com/1471-244X/7/33
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while the level of impairment was mild in 84 (15.0%),
moderate in 201 (35.8%) and severe in 71 (12.7%); 100
(17.8%) were unable to work due to mental illness.
Thirty-three patients (5.9%) were very satisfied with his/
her life, 126 (22.5%) were satisfied, 171 (30.5%) were
neither satisfied nor dissatisfied, 169 (30.2%) were dissat-
isfied and 61 (10.9%) were very dissatisfied.
Clinical status
The mean overall CGI-BP score in the past year was 4.2 (±
1.1). The mean score at baseline was 4.4 (± 0.9) both in
overall and mania, 1.9 (± 1.2) in depression, and 2.6 (±
1.6) in hallucinations/delusions (which were reported in
202 patients, 36.8%). The number and proportion of
patients who were markedly, severely or very severely ill at
baseline was 235 (42.0%) in total score, 244 (43.6%) in
the mania score, 15 (2.7%) in the depression score and 86
(15.3%) in the hallucinations/delusions score. The dura-
tion of the episode of mania at baseline was < 1 week in
157 patients (28.1%), 1–2 weeks in 188 (33.6%), 3–4
weeks in 99 (17.7%), 5–8 weeks in 61 (10.9%), and > 8
weeks in 54 (9.7%). The results of the YMRS single items
are presented in Table 2. A total of 81 patients (14.4%)
had a total score < 12, 141 (25.1%) had a score ≥ 12 and
< 20, 340 (60.5%) had a score ≥ 20 (one patient was not
evaluated). The mean total score of HAM-D was 3.0 (±
2.5). The results of the Life Chart Method in the week
prior to enter the study showed that the mean values were
5.7 (± 2.7) for mania, 0.5 (± 1.4) for depression and 5.9
(± 2.5) as overall score.
Medication's prescription at baseline
In the past 4 weeks prior to baseline, 316 patients (56.2%)
were fully compliant to prescribed medication, 140
(24.9%) were compliant approximately half of time, 55
(9.8%) were almost never compliant and 51 (9.1%) were
not on drugs. Lack of efficacy was the main reason for
starting with a new medication at baseline and was
reported in 317 patients (57.3%). Other reasons were no
intake of previous medication (66, 11.9%), poor compli-
ance (50, 9.0%), patient's request (8.0% of patients) and
side-effects (5.8%). The most common adverse events
reported with treatment taken prior to baseline visit were
loss of memory/difficulties in concentration (in 245
patients, 43.6%), akatisia (in 231 patients, 41.3%), seda-
tion (in 207, 36.8%) and insomnia (in 201, 35.8%).
The distribution of patients according to the number of
psychotropic drugs taken before baseline and prescribed
at baseline is shown in Figure 1. The most common drugs
taken before baseline in each class (monotherapy, co-
therapy, more than two drugs) are presented in Table 3.
Seventy-five patients (13.7%) were naïve to treatment.
Among patients receiving monotherapy before baseline
(n = 186, 34.1%), 51 (27.4%) were treated with atypical
antipsychotic agents, 63 (33.9%) with typical agents, 45
Table 1: Patients' psychiatric history
Characteristic Results
Age at onset of mood symptoms, mean ± SD (range):
Age at first symptoms of bipolar disorder 29.7 ± 11.1 (2–77) years
Age at onset of manic or mixed episodes 31.4 ± 11.8 (2–77) years
Age at onset of depressive episodes 31.3 ± 11.9 (0–74) years
Age at start of treatment mean ± SD (range):
Age at first treatment of mood symptoms 31.3 ± 10.9 (13–74) years
Age at first contact with psychiatric services 32.9 ± 12.0 (13–74) years
Age of first admission for psychiatric symptoms 32.9 ± 12.2 (0–79) years
Psychiatric services used in the past 12 months, mean ± SD (range):
Number of admissions due to bipolar disorders 1.1 ± 3.8 (0–61)
Number of days in inpatient facility 10.7 ± 20.3 (0–148)
Number of days in day care 5.2 ± 25.0 (0–300)
Number of outpatients consultations 10.6 ± 13.5 (0–100)
Number (%) of Alcohol users/abusers/dependents.
Users 129 (23.3)
Abusers 42 (7.6)
Dependant 4 (0.7)
Number (%) of Cannabis: users/abusers/dependents
Users 30 (5.5)
Abusers 13 (2.4)
Dependant 2 (0.4)
Number (%) of other substances users/abusers/dependents
Users 8 (1.4)
Abusers 10 (1.8)
Dependant 2 (0.4)BMC Psychiatry 2007, 7:33 http://www.biomedcentral.com/1471-244X/7/33
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(24.1%) with other anticonvulsants, and 27 (14.5%) with
lithium. The most common combinations (n = 285,
52.2%) were typical + anticonvulsants (in 55 patients,
19.3%), atypical + anticonvulsants (in 40, 14.0%), typical
+ atypical + anticonvulsants (in 30, 10.5%), typical + lith-
ium (in 28, 9.8%) and typical + lithium + anticonvulsants
(in 27, 9.5%). With regards to intramuscular therapies, 96
patients (12.3%) were taking fast-acting typical agents, 19
(3.4%) fast-acting atypical agents, 61 (11.0%) benzodi-
azepines and 9 (1.6%) other fast-acting medications.
The most common drugs prescribed at baseline in each
class are presented in Table 4. Among prescribed mono-
therapies (n = 137, 24.8%), 87 patients (63.5%) received
atypical antipsychotic agents, 10 (7.3%) typical agents, 31
(22.6%) other anticonvulsants, and 9 (6.6%) lithium. The
most commonly prescribed combinations (n = 415,
75.2%) were atypical + anticonvulsants (in 147 patients,
35.5%), atypical + lithium (62, 14.9%), typical + atypical
+ anticonvulsants (in 43, 10.4%) and atypical + lithium +
anticonvulsants (in 34, 8.2%).
Antidepressants were taken prior to baseline by 135
patients (24.7%) as SSRI, by 36 (6.58%) as TCAs and by
16 (2.9%) in form of other medications; the correspond-
ing prescribed numbers were 71 (13.0%), 7 (1.3%) and
(0.7%). Benzodiazepines were taken prior to baseline by
379 patients (69.3%) and were then prescribed in 326
(59.2%).
Discussion
The EMBLEM study is the first prospective observational
survey focusing on the patterns of drugs prescribed, the
therapeutic management and the outcomes of a large
sample of patients affected by bipolar mania in 14 Euro-
pean countries [4]. In particular, the Italian cohort may be
particularly interesting as it represents a "more naturalis-
tic" sample of patients treated in routine clinical practice,
Table 3: Drug treatment registered at baseline (before change) by class
Monotherapy (n = 186) Co-therapy with 2 drugs (n = 150) Polytherapy (> 2 drugs) (n = 135)
Drug N (%) Drugs N (%) Drugs N (%)
Haloperidol 45 (24.2) Other typical/atypical 15 (10.0) Haloperidol/other typicals/other AC 11 (8.2)
Valproate 31 (16.7) Haloperidol/Lithium 12 (8.0) Haloperidol/other typicals/Valproate 11 (8.2)
Lithium 27 (14.5) Olanzapine/Valproate 10 (6.7) Haloperidol/other typicals/Lithium 8 (5.9)
Olanzapine 19 (10.2) Risperidone/non-valproate AC 10 (6.7) Other typicals/other AC/Lithium 8 (5.9)
Other typical 18 (9.7) Other typical/Valproate 10 (6.7) Haloperidol/other typicals 3 (2.2)
Risperidone 16 (8.6) Risperidone/Lithium 9 (6.0) Other typicals/Valproate/Lithium 2 (1.5)
Other AC 14 (7.6) 2 typicals 9 (6.0) Other combinations 92 (68.1)
Quetiapine 10 (5.4) Other typical/Lithium 8 (5.3)
Other atypical 6 (3.2) Haloperidol/Valproate 8 (5.3)
Lithium/non-valproate AC 8 (5.3)
Olanzapine/Lithium 7 (4.7)
Haloperidol/non-valproate AC 7 (4.7)
Other combinations 37 (24.7)
AC = Anticonvulsivants;
Table 2: Score of Young Mania Rating Scale by single items
Item Mean ± SD (range)
Elevated mood 2.2 ± 1.1 (0–4)
Increased motor activity-energy 2.3 ± 1.0 (0–4)
Sexual interest 1.1 ± 1.1 (0–4)
Sleep 2.1 ± 1.2 (0–4)
Irritability 3.2 ± 1.9 (0–8)
Speech (rate and amount) 3.3 ± 1.9 (0–8)
Language-thought disorder 1.5 ± 0.9 (0–4)
Content 3.1 ± 2.5 (0–8)
Disruptive-aggressive behaviour 1.5 ± 1.6 (0–8)
Appearance 1.2 ± 1.1 (0–4)
Insight 1.6 ± 1.4 (0–4)
Total score 22.9 ± 10.2 (4–57)BMC Psychiatry 2007, 7:33 http://www.biomedcentral.com/1471-244X/7/33
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because no restricted treatment assignment was adopted
in the protocol.
The study was designed with no restrictive inclusion and
exclusion criteria in order to have an as much as possible
wide representation of patients receiving treatment for
acute mania in the context of bipolar disorder. The
EMBLEM provides relevant clinical and epidemiological
information on the psychotropic drugs treatment pre-
scribed in a real-world situation to bipolar in- and outpa-
tients as well as on the effectiveness of these treatments at
baseline and during a follow-up of 24 months.
A previous survey performed in Europe that involved
more than 10 countries, the GAMIAN-Europe/BEAM Sur-
vey [10], showed some similarities in problems and diffi-
culties encountered in the management of bipolar
patients across different countries, regardless of the polit-
ical, social or cultural settings. Social functioning and
integration of patients with bipolar disorders were shown
to be still poor and education of bipolar patients about
drug treatment and psychosocial interventions were
found to be still a healthcare priority [11]. However, the
relatively low amount of patients observed, which pro-
vided little country-specific information, and the lack of
longitudinal data over time represented relevant limita-
tions of the study.
The baseline data coming from the Italian cohort of the
EMBLEM study have shown some relevant information
about the characteristics and the pattern of drug used in
patients with acute bipolar mania. Most of the subjects
observed (66.8%) were outpatients and about half had a
good educational level. Data of onset of psychiatric symp-
toms showed that manic or mixed and depressive epi-
sodes started at a similar mean age. A recent survey of the
Stanley Foundation Bipolar Network (SFBN) that
included bipolar patients [12] showed an earlier age at
onset compared to that of the present study (i.e. approxi-
mately 21 vs. 30 years on average) and that age of onset of
depression preceded the date of onset of mania or mixed
states of 4 years on average. In the view that the mean age
at first onset generally reflects the polarity of the disorder,
as shown in a recent retrospective analysis [13], the simi-
lar mean age at onset of manic/mixed and depressive
symptoms found in this study may be as indicator of a
lack of predominance of one pole over the other in our
sample.
Distribution of patients according to the number of psycho- tropic drugs taken before/prescribed at baseline Figure 1
Distribution of patients according to the number of psycho-
tropic drugs taken before/prescribed at baseline. Data of 
drugs taken before baseline and prescribed at baseline were 
missing in 9 and in 3 patients, respectively.
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Table 4: Drug treatment prescribed at baseline (after change) by class
Monotherapy (n = 137) Co-therapy with 2 drugs (n = 264) Polytherapy (> 2 drugs) (n = 151)
Drug N (%) Drugs N (%) Drugs N (%)
Olanzapine 69 (50.4) Olanzapine/Valproate 59 (22.3) Olanzapine/Valproate/Lithium 11 (7.3)
Valproate 21 (15.3) Olanzapine/Lithium 39 (14.8) Olanzapine/other AC/Lithium 10 (6.6)
Risperidone 11 (8.0) Olanzapine/non-valproate AC 34 (12.9) Olanzapine/other typicals/Valproate 8 (5.3)
Other AC 10 (7.3) Risperidone/Valproate 19 (7.2) Olanzapine/other typicals/other AC 7 (4.6)
Lithium 9 (6.6) Other typical/atypical 16 (6.1) Olanzapine/other typicals/lithium 2 (1.3)
Quetiapine 6 (4.4) Risperidone/Lithium 14 (5.3) Other combinations 113 (74.8)
Haloperidol 6 (4.4) Other atypical/Valproate 11 (4.2)
Other typical 4 (2.9) Haloperidol/Lithium 9 (3.4)
Other atypical 1 (0.7) Other atypical/non-valproate AC 7 (2.7)
Other typical/Lithium 7 (2.7)
2 typicals 7 (2.7)
Other typical/non-valproate AC 6 (2.3)
Risperidone/non-valproate AC 6 (2.3)
Other combinations 30 (11.4)
AC = Anticonvulsivants;BMC Psychiatry 2007, 7:33 http://www.biomedcentral.com/1471-244X/7/33
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Only a minority of patients attended the clinics at the first
episode, while approximately half of them had at least 2
manic or mixed episodes and more than 70% had manic,
mixed or depressive episodes in the last 12 months. The
time from the first onset of symptoms of bipolar disorder
to the start of treatment was relatively short (on average
18 months); however, the first contact with a psychiatric
service was taken on average 18 months after a treatment
was started, presumably in a non-psychiatric setting. The
lag time from the first symptoms and treatment was mark-
edly lower than that found in the survey of the SFBN, in
which first treatment for bipolar patients had been
delayed by an average of 10 years from illness onset [14].
The analysis of co-morbidities showed that substance-use
disorders, which are frequently associated with mood dis-
orders and may negatively influence their course and out-
come [15,16], were reported in a relatively small amount
of subjects. Consistently with other reports [17], approxi-
mately one fifth of patients had alcohol-correlated disor-
ders in the past and less than 10% were abusers or
dependent at study entry. This relatively low amount of
substance-abuse disorders is likely to be the result of the
healthcare organization in Italy, which includes specific
services dedicated to drugs users and hence a lower refer-
ral to psychiatric services.
A total number of 117 patients (21.1%) attempted sui-
cide, and 26 (4.7%) in the previous 12 months. The risk
of suicide appears to be in line with findings of some sur-
veys [18] but much lower than that reported in others
[19], possibly due to the relatively late onset of bipolar
disorders in this population. Consistently with the results
reported by the SFBN [14], patients admitted to this study
had severe limitation of social and occupational function-
ing: 48.3% had moderate or severe impairment of occupa-
tional activities and a further 17.8% was totally unable to
work due to mental illness.
The distribution of CGI-BP also showed a high level of
impairment. The mean baseline mean score of mania
(4.4) was higher than the score of depression (1.9) and of
hallucinations/delusions (2.6). Accordingly, 60.5% of
patients had an YMRS score ≥ 20. The main reason of the
start/change of prescription were lack of efficacy of the
ongoing therapy (57.3% of patients), which accounted for
lack of compliance and the need for alternative treatment
in a significant proportion of patients. A high rate of
patients also reported poor tolerability of the current ther-
apies, which were taken in 86.3% of patients.
The start/change of prescription at baseline led to a low
number of patients with prescribed monotherapy (24.8%
vs. 34.1%) and to an increasing of combined therapies,
with 75.2% of patients with prescribed combinations
compared to 52.2% of patients taking combined therapies
at baseline. Among patients with monotherapy, prescrip-
tion of atypical antipsychotics increased from 27.4% of
patients to 63.5%, while typical agents decreased from
33.9% to 7.3%; prescription of lithium and other anticon-
vulsants as single agent was also reduced.
The most commonly antipsychotics prescribed in combi-
nation, were represented by atypical agents. The prescrip-
tion of olanzapine in monotherapy increased from
approximately 10% to 50% of patients, and also was the
most prescribed agent both in co-therapy (in 22.3% of
patients with valproic acid, in 14.8% with lithium and in
12.9% with other antimanic drugs) and in polytherapy
with 3 or more drugs. The prescription of antidepressants
and to a lesser extent of benzodiazepines, decreased com-
pared to pre-baseline condition.
Therefore, based on the patients' baseline condition, sub-
stantial changes of drug treatment were reported. A wide
spectrum of therapies was prescribed in patients assigned
to dual therapy and, in a greater extent, in those pre-
scribed with 3 or more drugs.
This survey presents some limitations: this study included
patients who needed to initiate or to change their drug
treatment due to the acute episode of mania; respect to
this, the reliability of CGI-BP to assess the symptoms in
the past year may be questionable. Furthermore, our sam-
ple size could be not adequately powered to draw reliable
conclusion on effects of drugs prescribed in the longitudi-
nal phase of the study in the view of the high variability of
treatments.
Conclusion
The baseline data collected in the Italian cohort of
patients taking part in the EMBLEM study showed a high
degree of clinical and functional impairment at baseline
and great and variable changes in drug prescriptions.
However, patients enrolled in Italy represent an adequate
sample to address country-specific information on clini-
cal, social and economic outcomes in the management of
acute bipolar mania. The analyses of the follow-up data
concerning the management of the bipolar patients from
the Italian cohort of the EMBLEM study are still in
progress.
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